共 50 条
- [1] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Gibbs, PeterHeinemann, VolkerSharma, Navesh K.Findlay, Michael P. N.Ricke, JensPeeters, MarcPerez, DavidRobinson, Bridget AnneStrickland, AndrewFerguson, TomRodriguez, JavierKroening, HendrikWolf, IdoGanju, VinodWalpole, Euan ThomasBoucher, EvelineTichler, Thomas E.Gebski, ValVan Buskirk, MarkVan Hazel, Guy A.
- [2] SIRFLOX: RANDOMISED PHASE III TRIAL COMPARING FIRST-LINE MFOLFOX6 ± BEVACIZUMAB (BEV) VERSUS MFOLFOX6 ± BEV plus SELECTIVE INTERNAL RADIATION THERAPY (SIRT) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) - ANALYSIS BY PRESENCE OR ABSENCE OF EXTRA-HEPATIC METASTASES, BEV TREATMENT AND SITE OF FIRST PROGRESSIONAsia-Pacific Journal of Clinical Oncology, 2015, 11 : 68 - 69Gibbs, Petervan Hazel, Guy A.Heinemann, VolkerSharma, Navesh K.Findlay, Michael P. N.Ricke, JensPeeters, MarcPerez, DavidRobinson, BridgetStrickland, AndrewFerguson, TomRodrigez, JavierKroening, HendrikWolf, IdoGanju, VinodWalpole, EuanBoucher, EvelineTichler, ThomasGebski, ValVan Buskirk, Mark
- [3] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +van Hazel, Guy A.Heinemann, VolkerSharma, Navesh K.Findlay, Michael P. N.Ricke, JensPeeters, MarcPerez, DavidRobinson, Bridget A.Strickland, Andrew H.Ferguson, TomRodriguez, JavierKroening, HendrikWolf, IdoGanju, VinodWalpole, EuanBoucher, EvelineTichler, ThomasShacham-Shmueli, EinatPowell, AlexEliadis, PaulIsaacs, RichardPrice, DavidMoeslein, FredTaieb, JulienBower, GeoffGebski, ValVan Buskirk, MarkCade, David N.Thurston, KennethGibbs, Peter
- [4] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059van Hazel
- [5] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)Yoshino, TakayukiWatanabe, JunShitara, KoheiYasui, HirofumiOhori, HisatsuguShiozawa, ManabuYamazaki, KentaroOki, EijiSato, TakeoNaitoh, TakeshiKomatsu, YoshitoKato, TakeshiHihara, MasamitsuSoeda, JunpeiYamamoto, KoujiAkagi, KiwamuOchiai, AtsushiUetake, HiroyukiTsuchihara, KatsuyaMuro, Kei
- [6] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595Schmoll, Hans-JoachimCunningham, DavidSobrero, AlbertoKarapetis, Christos S.Rougier, PhilippeKoski, Sheryl L.Kocakova, IlonaBondarenko, IgorBodoky, GyoergyMainwaring, PaulSalazar, RamonBarker, PeterMookerjee, BijoyeshRobertson, JaneVan Cutsem, Eric
- [7] Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Lenz, Heinz-JosefParikh, Aparna RajSpigel, David R.Cohn, Allen LeeYoshino, TakayukiKochenderfer, Mark D.Elez, ElenaShao, Spencer H.Deming, Dustin A.Holdridge, Regan C.Larson, TimothyChen, EricMahipal, AmitUcar, AntonioCullen, DanaBaskin-Bey, Edwina S.Ledeine, Jean-MarieHammell, AmyTabernero, Josep
- [8] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Heinrich, KathrinHeinemann, VolkerWestphalen, BenediktOecal, OsmanVan Hazel, Guy A.Gibbs, PeterSeidensticker, MaxRicke, JensSeidensticker, Ricarda
- [9] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancerANNALS OF ONCOLOGY, 2020, 31 : S92 - S92Belhadef, S.Arab, A.Belmadi, M.Beninal, M.Bacha, N.Abdallah, R.Mechta, K.Dahmane, A.Mahfouf, H.Oukkal, M.Bouzid, K.Faraqun, S.Bentabak, K.Younes, S. Ait
- [10] A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Joseph, Mathew JohnBarnes, KirkBlachly, RonaldKuzur, Michel E.Bendell, Johanna C.